FBR analyst Vernon Bernardino was out today with a mix report on shares of Galena Biopharma Inc (NASDAQ:GALE), reiterating an Outperform rating while slashing the …
Analyst Jason McCarthy of Maxim Group maintained a Buy rating for Galena Biopharma Inc (NASDAQ:GALE), but decreased his price target to $2, marking a 340% increase …
Galena Biopharma Inc (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major medical needs, today announced …
FBR analyst Vernon Bernardino weighed in on Galena Biopharma Inc (NASDAQ:GALE), after the company announced that its Independent Data Monitoring Committee completed an interim analysis …
Healthcare analysts are weighing in on biotech companies Galena Biopharma Inc (NASDAQ:GALE) and Lipocine Inc (NASDAQ:LPCN), as shares of both companies fell sharply today, reaching record …
Galena Biopharma Inc (NASDAQ:GALE) is plummeting 80% in early morning trading after the company discontinued its phase 3 interim analysis on Neuvax, its …
Galena Biopharma Inc (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, announced …
Amid drug trials and pipeline updates, analysts remain bullish on both Galena Biopharma Inc (NASDAQ:GALE) and Marinus Pharmaceuticals Inc (NASDAQ:MRNS). Analysts dive into …
Galena Biopharma Inc (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, …
Galena Biopharma Inc (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today …
